Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lutathera's Long-Term safety under the microscope in 1,000+ patients

NCT ID NCT03691064

First seen Jan 09, 2026 · Last updated May 20, 2026 · Updated 18 times

Summary

This study looks at the long-term safety of Lutathera, a treatment for advanced neuroendocrine tumors that cannot be removed by surgery or have spread. Over 1,000 adults who have already received Lutathera are being followed to track any new cancers, side effects, and overall survival. No new treatment is given; the goal is to understand risks over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Banner MD Anderson Cancer Center

    Phoenix, Arizona, 85006, United States

  • Novartis Investigative site

    Clichy, France

  • Novartis Investigative site

    Lyon, France

  • Novartis Investigative site

    Villejuif, France

  • Novartis Investigative site

    Coimbra, Coimbra District, 3000-075, Portugal

  • Novartis Investigative site

    Santiago de Compostela, La Corunya, 15706, Spain

  • Novartis Investigative site

    Majadahonda, Madrid, 28222, Spain

  • Novartis Investigative site

    Birmingham, B152WB, United Kingdom

  • Novartis Investigative site

    Cambridge, CB2 0QC, United Kingdom

  • Novartis Investigative site

    Glasgow, G12 OYN, United Kingdom

  • Novartis Investigative site

    Liverpool, L7 8XP, United Kingdom

  • Novartis Investigative site

    London, NW32QG, United Kingdom

  • Novartis Investigative site

    London, SE1 9RT, United Kingdom

  • Novartis Investigative site

    London, SE5 9RS, United Kingdom

  • Novartis Investigative site

    London, W6 8RF, United Kingdom

  • Novartis Investigative site

    Manchester, United Kingdom

  • Novartis Investigative site

    Sheffield, S102SJ, United Kingdom

  • Oregon Health & Sciences University Hospital

    Portland, Oregon, 97339, United States

  • The Ohio State University Wexner Medical Center

    Portland, Ohio, 43210, United States

  • Virginia Mason in Seattle

    Seattle, Washington, 98101, United States

Conditions

Explore the condition pages connected to this study.